OptimizeRx Q3 sales fall on contracted revenue; lowers annual revenue outlook

By Reuters News


Overview

  • Healthcare technology firm's Q3 revenue fell 17% yr/yr but beat analyst expectations

  • Q3 adjusted EPS and adjusted EBITDA both beat analyst expectations

  • Company updated 2026 revenue guidance to $87-$93 mln, citing lower contracted revenue


Outlook

  • Company updates 2026 revenue outlook to $87-$93 mln

  • Company maintains 2026 adjusted EBITDA guidance at $21-$25 mln

  • Company sees renewed Q4 spending from a previously significant customer and pent-up demand for 2027 RFP season


Result Drivers

  • MARGIN EXPANSION - Co said adjusted EBITDA margin expanded over 900 basis points due to improved product mix and cost management initiatives

  • CUSTOMER SPENDING - Co cited renewed spending in Q4 from a previously significant customer and expanding opportunities within key accounts

  • AI PLATFORM - Co said its scalable AI-enabled platform and proprietary healthcare data are competitive advantages supporting future growth


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$21.60 mln

$21.19 mln (6 Analysts)

Q3 Adjusted EPS

Beat

$0.20

$0.17 (6 Analysts)

Q3 Adjusted Net Income

Beat

$3.80 mln

$3.21 mln (5 Analysts)

Q3 Adjusted EBITDA

Beat

$6.30 mln

$4.10 mln (6 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the online services peer group is "buy"

  • Wall Street's median 12-month price target for OptimizeRx Corporation is $11.00, about 17.6% above its November 10 closing price of $9.35

  • The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 6 three months ago


Reuters Recommended Reads

  • Nov 9 - Trade Desk Q3 revenue beats analyst estimates

  • Nov 9 - Virtus Investment Partners Q3 adjusted EPS beats estimates

  • Nov 9 - ImmunityBio Q3 revenue rises on Anktiva sales growth but misses estimates


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk